IMM 1.49% 34.0¢ immutep limited

Media, page-682

  1. 132 Posts.
    lightbulb Created with Sketch. 78
    I think this slide very well may be the most important in the new deck. Eftilagimod alpha very well may turn NSCLC and HNSCC into PD-L1 all comers, but knowing who’s like to clinically benefit once on drug could be the key. I bet Merck scientists or the FDA had something to do with this, as in creating boxes to check in the trial. Having a biomarker plan explaining response is “the way”. https://www.immutep.com/files/content/investor/presentation/2024/Immutep%20Corporate%20Presentation%20March%202024.pdfhttps://hotcopper.com.au/data/attachments/6065/6065699-fa5c40cfca6c4ae44ca2cce43e45abc1.jpg

 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
34.0¢
Change
0.005(1.49%)
Mkt cap ! $493.8M
Open High Low Value Volume
33.5¢ 34.0¢ 33.0¢ $1.220M 3.642M

Buyers (Bids)

No. Vol. Price($)
3 57289 33.0¢
 

Sellers (Offers)

Price($) Vol. No.
34.0¢ 52306 3
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.